BACKGROUND Tertiary lymphoid structures (TLSs) are organized aggregates of immune
cells that form postnatally in nonlymphoid tissues. TLSs are not found under physiological …

Cancer development and its response to therapy are regulated by inflammation, which
either promotes or suppresses tumor progression, potentially displaying opposing effects on …

The presence of intratumoral tertiary lymphoid structures (TLS) is associated with positive
clinical outcomes and responses to immunotherapy in cancer. Here, we used spatial …

Inhibitors of the programmed cell death-1 (PD-1/PD-L1) signaling axis are approved to treat
non-small cell lung cancer (NSCLC) patients, based on their significant overall survival (OS) …

The clinical success of cancer immune checkpoint blockade (ICB) has refocused attention
on tumor-infiltrating lymphocytes (TILs) across cancer types. The outcome of immune …

Tumors are not only aggregates of malignant cells but also well-organized complex
ecosystems. The immunological components within tumors, termed the tumor immune …

Abstract Treatment with immune checkpoint blockade (ICB) has revolutionized cancer
therapy. Until now, predictive biomarkers,,,,,,,,–and strategies to augment clinical response …

Activated B cells participate in either extrafollicular (EF) or germinal center (GC) responses.
Canonical responses are composed of a short wave of plasmablasts (PBs) arising from EF …

Soft-tissue sarcomas represent a heterogeneous group of cancer, with more than 50
histological subtypes,. The clinical presentation of patients with different subtypes is often …

Simple Summary Immunotherapies have revolutionized the field of cancer therapeutics, yet
a substantial subset of patients fail to respond. Recent efforts have focused on identifying …